Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

63.79 +3.02 (+4.97%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 947,769
Open 61.11
Bid (Size) 62.55 (1)
Ask (Size) 63.79 (4)
Prev. Close 60.77
Today's Range 60.41 - 64.00
52wk Range 42.51 - 158.26
Shares Outstanding 77,457,081
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Jim Cramer Says This Company Isn't Making Money
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he is hearing nothing but positives of late about Nokia Corp (NYSE: NOK) over the previous four weeks. "I think it’s right to buy," he added. 
Via Benzinga
Evercore ISI Group Downgrades CRISPR Therapeutics: Here's What You Need To Know
Evercore ISI Group downgraded its rating of CRISPR Therapeutics (NASDAQ:CRSP) to In-Line with a price target of $60.00, changing its price target from $66.00 to $60.00. Shares of CRISPR Therapeutics... 
Via Benzinga

Performance

YTD
-21.93%
-21.93%
1 Month
+4.57%
+4.57%
3 Month
-8.23%
-8.23%
6 Month
-21.93%
-21.93%
1 Year
-59.08%
-59.08%

More News

Read More
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022
Via Benzinga
Why CRISPR Therapeutics Stock Is Falling
Via Benzinga
Chardan Capital Maintains Buy Rating for CRISPR Therapeutics: Here's What You Need To Know
Via Benzinga
Bear Market Rally Lifts HealthCare Stocks Off Bottom
Via Talk Markets
CNBC's Final Trades: Ethereum, Charles Schwab, Clean Energy, Boeing And This Biotech Stock
Via Benzinga
Do Crispr And Vertex Have A 'Functional Cure' For Blood Diseases?
Via Investor's Business Daily
Analyst Ratings for CRISPR Therapeutics
Via Benzinga
93 Biggest Movers From Yesterday
Via Benzinga
Analysts Consider CRISPR Therapeutics' Blood Disorder Trial Data Encouraging, Impressive
Via Benzinga
70 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
How Global Blood Therapeutics Thinks It Can Take On Crispr's Gene Editing
Via Investor's Business Daily
7 No-Brainer Biotech Stocks to Add to Your Buy List
Via InvestorPlace
7 Oversold Stocks to Buy Right Now
Via InvestorPlace
Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
IBD Tech Leader Vertex Snags Upgrade As Non-Cystic Fibrosis Drugs Crystallize
Via Investor's Business Daily
Cathie Wood Provides Lesson of the Day: Don't Invest in Fairytale Stocks
Via Talk Markets
Why Orphan Drug Designation Offers Several Benefits
Via FinancialNewsMedia
Exposures Product Safety
Analyst Ratings for CRISPR Therapeutics
Via Benzinga
How to Buy Stocks in a Recession
Via InvestorPlace
5 Cathie Wood Stocks to Buy Now
Via InvestorPlace
Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis
Via Investor's Business Daily
Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.